IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
Proteomics and Metabolomics Facility (ProMeFa), IRCCS San Raffaele Scientific Institute, Milan, Italy.
J Proteomics. 2021 Feb 10;232:104069. doi: 10.1016/j.jprot.2020.104069. Epub 2020 Dec 10.
Conditioned medium (CM) and extracellular vesicles (EV) from Adipose-derived Stem/stromal cells (ASC) and Dermal fibroblasts (DF) represent promising tools for therapeutic applications. Which one should be preferred is still under debate and no direct comparison of their proteome has been reported yet. Here, we apply quantitative proteomics to explore the protein composition of CM and EV from the two cell types. Data are available via ProteomeXchange (identifier PXD020219). We identified 1977 proteins by LC-MS/MS proteomic analysis. Unsupervised clustering analysis and PCA recognized CM and EV as separate groups. We identified 68 and 201 CM and EV specific factors. CM were enriched in proteins of endoplasmic reticulum, Golgi apparatus and lysosomes, whereas EV contained a large amount of GTPases, ribosome and translation factors. The analysis of ASC and DF secretomes revealed the presence of cell type-specific proteins. ASC-CM and -EV carried factors involved in ECM organization and immunological regulation, respectively. Conversely, DF-CM and -EV were enriched in epithelium development associated factors and -EV in Wnt signaling factors. In conclusion, this analysis provides evidence of a different protein composition between CM and EV and of the presence of cell type-specific bioactive mediators suggesting their specific future use as advanced therapy medicinal products. SIGNIFICANCE: The use of cell secretome presents several advantages over cell therapy such as the lower risks associated to the administration step and the avoidance of any potential risk of malignant transformation. The main secretome preparations consist in concentrated conditioned medium (CM) and extracellular vesicles (EV). Both of them showed well-documented therapeutic potentials. However, it is still not clear in which case it should be better to use one preparation over the other and an exhaustive comparison between their proteome has not been performed yet. The choice of the cell source is another relevant aspect that still needs to be addressed. In order to shed light on these questions we explored the protein composition of CM and EV obtained from Adipose-derived Stem/stromal Cells (ASC) and Dermal Fibroblasts (DF), by a comprehensive quantitative proteomics approach. The analysis showed a clear distinction between CM and EV proteome. CM were enriched in proteins of endoplasmic reticulum, Golgi apparatus and lysosomes, whereas EV contained a large amount of GTPases, ribosome and translation-related factors. Furthermore, the analysis of ASC and DF secretomes revealed specific biological processes for the different cell products. ASC secretome presented factors involved in ECM organization (hyaluronan and glycosaminoglycan metabolism) and immunological regulation (e.g. macrophage and IkB/NFkB signaling regulation), respectively. On the other hand, DF-CM and -EV were both enriched in epithelium development associated factors, whilst DF-CM in proteins involved in cellular processes regulation and -EV in Wnt signaling factors. In conclusion, our study shed a light on the different protein composition of CM and EV of two promising cell types, spanning from basic processes involved in secretion to specific pathways supporting their therapeutic potential and their possible future use as advanced therapy medicinal products.
条件培养基 (CM) 和细胞外囊泡 (EV) 来源于脂肪来源的干细胞/基质细胞 (ASC) 和真皮成纤维细胞 (DF),它们是治疗应用的有前途的工具。目前仍在争论应该选择哪一种,并且尚未对它们的蛋白质组进行直接比较。在这里,我们应用定量蛋白质组学来探索两种细胞类型的 CM 和 EV 的蛋白质组成。数据可通过 ProteomeXchange(标识符 PXD020219)获得。通过 LC-MS/MS 蛋白质组学分析,我们鉴定了 1977 种蛋白质。无监督聚类分析和 PCA 识别 CM 和 EV 为单独的组。我们鉴定了 68 种 CM 和 201 种 EV 特异性因子。CM 富含内质网、高尔基体和溶酶体的蛋白质,而 EV 则含有大量的 GTP 酶、核糖体和翻译因子。对 ASC 和 DF 分泌组的分析揭示了细胞类型特异性蛋白质的存在。ASC-CM 和 -EV 分别携带参与细胞外基质组织和免疫调节的因子。相反,DF-CM 和 -EV 富含与上皮细胞发育相关的因子,而 -EV 富含 Wnt 信号因子。总之,该分析提供了 CM 和 EV 之间蛋白质组成存在差异的证据,以及存在细胞类型特异性生物活性介质的证据,这表明它们可作为高级治疗药物产品的特殊用途。
细胞分泌物的使用与细胞治疗相比具有许多优势,例如与给药步骤相关的风险较低,并且可以避免任何潜在的恶性转化风险。主要的分泌物制剂包括浓缩的条件培养基 (CM) 和细胞外囊泡 (EV)。它们都具有良好的治疗潜力。然而,目前尚不清楚在何种情况下最好使用一种制剂而不是另一种制剂,并且尚未对它们的蛋白质组进行详尽的比较。细胞来源的选择是另一个需要解决的相关方面。为了阐明这些问题,我们通过全面的定量蛋白质组学方法,探索了从脂肪来源的干细胞/基质细胞 (ASC) 和真皮成纤维细胞 (DF) 中获得的 CM 和 EV 的蛋白质组成。分析表明 CM 和 EV 蛋白质组之间存在明显区别。CM 富含内质网、高尔基体和溶酶体的蛋白质,而 EV 则富含大量 GTP 酶、核糖体和翻译相关因子。此外,对 ASC 和 DF 分泌组的分析揭示了不同细胞产物的特定生物学过程。ASC 分泌组呈现出与细胞外基质组织 (透明质酸和糖胺聚糖代谢) 和免疫调节 (例如巨噬细胞和 IkB/NFkB 信号调节) 相关的因子。另一方面,DF-CM 和 -EV 都富含与上皮细胞发育相关的因子,而 DF-CM 富含参与细胞过程调节的因子,-EV 富含 Wnt 信号因子。总之,我们的研究阐明了两种有前途的细胞类型的 CM 和 EV 的不同蛋白质组成,涵盖了从涉及分泌的基本过程到支持其治疗潜力和可能作为高级治疗药物产品的未来用途的特定途径。